Boehringer Ingelheim Ditches Phase II Alzheimer's Program Post author:Sam Post published:February 8, 2018 Post category:BioPharma Another potential treatment for Alzheimer’s disease has been tossed into the rubbish bin. Source: BioSpace You Might Also Like Jobs Lost as Cellectar Biosciences Shutters Manufacturing Operations January 8, 2018 NW Bio Closes 3-Year Convertible Debt Exchange And Financing, And Completes Payoff Of Last $5 Million Of 2014 Bonds June 21, 2017 MorphoSys AG To Present At Upcoming Investor Conferences August 9, 2017
NW Bio Closes 3-Year Convertible Debt Exchange And Financing, And Completes Payoff Of Last $5 Million Of 2014 Bonds June 21, 2017